Clinical Trial Goal
To find out:
- The highest dose of Q702 that's safe to give with azacitidine and venetoclax
- If the combination of azacitidine, Q702 and venetoclax is safe and works well to treat AML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML that has relapsed or is refractory
- Do not have translocation t(15;17). Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Azacitidine is a drug that blocks the growth of cancer cells.
Q702 is a small molecule inhibitor that blocks Axl, Mer and CSF1R.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Q702 is a small molecule inhibitor that blocks Axl, Mer and CSF1R.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Azacitidine – Given as intravenous (IV) infusions or as a shot under your skin 1 time each day for 1 week
- Q702 – A pill that you take by mouth 1 time each day for 2 weeks
- Venetoclax – A pill that you take by mouth 1 time each day
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has not yet approved Q702.
Locations
MD Anderson Cancer CenterRECRUITING
Houston, Texas
Abhishek Maiti, MBBS, 713-745-3228, amaiti@mdanderson.org
Sponsors
collaborator: Qurient Co., Ltd., lead: M.D. Anderson Cancer Center
